## Contents

### Highlights of This Issue 1219

#### SPOTLIGHT ON CLINICAL RESPONSE

1221  Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent  
Siqing Fu, Aung Naing, Caroline Fu,  
Macus Tien Kuo, and Razelle Kurzrock

1226  New Directions for Biologic Targets in Urothelial Carcinoma  
Suzanne Richter and Srikala S. Sridhar

#### THERAPEUTIC DISCOVERY

1236  Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer  
Neil E. Bhola, Maria L. Freilino,  
Sonali C. Joyce, Malabika Sen,  
Suli M. Thomas, Anirban Sahu, Andre Cassell,  
Ching-Shih Chen, and Jennifer R. Grandis

1247  IGF-1R/MDM2 Relationship Confers Enhanced Sensitivity to RITA in Ewing Sarcoma Cells  
Giusy Di Conza, Marianna Buttarelli,  
Olimpia Monti, Marsha Pellegrino,  
Francesca Mancini, Alfredo Pontecorvi,  
Katia Scotlandi, and Fabiola Moretti

1257  Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth  
Christine Helsen, Arnaud Marchand,  
Patrick Chaltin, Sebastian Munck,  
Arnout Voet, Annemieke Verstuyf, and  
Frank Claessens

1269  Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation  
William P. Katt, Sekar Ramachandran,  
Jon W. Erickson, and Richard A. Cerione

1279  An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 trans-Presentation at the Tumor Site  
Vanessa Kermer, Volker Baum, Nora Hornig,  
Roland E. Kontermann, and Dafne Müller

### REVIEW

1289  STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression  
Shinji Kohsaka, Lei Wang, Kazuhiro Yachi,  
Roshan Mahabir, Takuhito Narita, Tamio Itoh,  
Mishie Tanino, Taichi Kimura,  
Hiroshi Nishihara, and Shinya Tanaka

1300  Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions  
Rona Ortenberg, Yair Sapir, Lee Raz,  
Liat Herskovicz, Ayelet Ben Arav,  
Siva Sapoznik, Iris Barshack, Camilla Avivi,  
Yackov Berkun, Michal J. Besser,  
Tehila Ben-Moshe, Jacob Schachter, and  
Gal Markel

#### HDL Mimetics Inhibit Tumor Development in Both Induced and Spontaneous Mouse Models of Colon Cancer  
Feng Su, Victor Grijalva, Kaveh Navab,  
Ekambaram Ganapathy, David Meriwether,  
Satoshi Imaizumi, Mohamad Navab,  
Alan M. Fogelman, Srivivasa T. Reddy, and  
Robin Farias-Eisner

#### Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells  
Sheng Tai, Yin Sun, Nan Liu, Boxiao Ding,  
Elaine Hsia, Sunita Bhuta, Ryan K. Thor,  
Robert Dimeo, Xiaozhao Liang, and  
Jiaoti Huang

### PRECLINICAL DEVELOPMENT

1332  Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs  
Ali R. Jazirehi and James S. Economou

1342  Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications  
Juan Carlos Montero, Xi Chen, Alberto Ocaña, and Atanasio Pandiella
The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models

Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
Kelly Davis Orcutt, John J. Rhoden, Benjamin Ruiz-Yi, John V. Frangioni, and K. Dane Wittrup

Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation
Vlad C. Sandulache, Heath D. Skinner, Yuan Wang, Yunyun Chen, Cristina T. Dodge, Thomas J. Ow, James A. Bankson, Jeffrey N. Myers, and Stephen Y. Lai

Correction: Microtubule Inhibitors: Differentiating Tubulin-Inhibiting Agents Based on Mechanisms of Action, Clinical Activity, and Resistance

ABOUT THE COVER
The CEACAM1 protein protects melanoma cells from cytotoxic lymphocytes in vitro via homophilic intercellular interactions. Immunohistochemistry of a human lymph node infiltrated with melanoma cells for CEACAM1 (brown pigmentation) and CD8 (pink pigmentation) showed that almost all CD8-positive lymphocytes in the tumor and its close vicinity were CEACAM1⁺, while most lymphocytes in other areas distant from tumor edge were mostly CEACAM1⁻. This strongly suggests that CEACAM1-mediated inhibition occurs in vivo and thus its blockade is a promising strategy for cancer immunotherapy. For details, see article by Ortenberg and colleagues on page 1300.